News

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.

According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration.

Proactive communication and leveraging advanced, yet reliable, technologies  to maximize efficiency are essential pillars of success.

We stand on the cusp of a new era in vitreoretinal surgery, one that has been marked by only a select few seminal innovations

A key distinction between patients seen in the clinic vs those enrolled in clinical trials has to do with characteristics dictated by the trial’s inclusion/exclusion criteria.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

The mapping method revealed prominent microscopic abnormalities consistent with DR

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Researchers from the Case Western Reserve University School of Medicine and the Cole Eye Institute have found that supplement melatonin could be linked to a decreased risk of age-related macular degeneration.

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than the standard bimonthly aflibercept control group at all 6 time points through Week 24.

Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Eleonora Lad, MD, PhD, discusses the stages of dry AMD from early to intermediate to geographic atrophy, while also assessing which endpoints are most useful for these different stages.

Investigators put forth a list of considerations for surgeons ahead of lens removal in pediatric patients

Authors pointed out that understanding this link may aid with genetic counseling or surveillance of affected individuals, potentially contributing to improved management and outcomes.

The primary endpoint for the ReNEW and ReGAIN trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography (SD-OTC) and ellipsoid zone mapping at week 48.

The IND approval will allow the company to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).

The company noted its OCT reference database now offers a library of 870 healthy eyes, more than tripling the previous versions.

Arshad M. Khanani, MD, MA, shares what attendees and the retina community can expect from the Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

The electromagnetic driving systems are proposed for the flexible 5-DOF magnetic manipulation of a micro-robot within the posterior eye, enabling precise targeted drug delivery.